SUMMARY Three children with azotaemic renal osteodystrophy were treated with 1,25-dihydroxycholecalciferol (1,25(OH)2D3). All showed clinical, biochemical, and radiological improvement within 6 months of starting treatment. There were no complications. al., 1975). These complications often affect the quality of life which can now be maintained and prolonged by regular dialysis and renal transplantation (Brickman et al., 1974; Henderson et al., 1974; Silverberg et al., 1975; Pierides et al., 1975) , but there are no reported studies in children and no dose recommendations are available. This paper describes our experience with longterm 1,25(OH)2D3 in 2 children aged 22 and 30 months, and in a 15-year-old boy. In 2 of the 3 cases uraemic osteodystrophy was complicated
. The baby became alert, gained in height and weight, and began to walk. At present, at the age 3 3 years he is still uraemic (plasma creatinine 319 ,umol/l; 3 *6 mg/100 ml) but remarkably well and has normal radiological skeletal appearances. Histological bone studies were not made.
Case 2. Presented soon after birth (born 24 Dec 1960) with the nephrotic syndrome due to focal glomerulosclerosis. At group.bmj.com on August 28, 2017 -Published by http://adc.bmj.com/ Downloaded from gressive renal failure developed. At 11 years he had a generalized convulsion and treatment with phenytoin was begun. Serum Ca was low, 1 4 mmol/l (5 -6 mg/100 ml), alkaline phosphatase 486 units/I, and plasma creatinine 730 ,cmol/l (8-3 mg/lOO ml).
Because of the hypocalcaemia, vitamin D2 10 000 units daily was given and the dose was raised to 50 000 units daily a month later. A transiliac bone biopsy in October 1972, one month after starting regular haemodialysis, showed mild osteitis fibrosa and moderate osteomalacia (Table) . In January 1974 he received a living-donor kidney transplant from his mother, but because of a recurrence of fits the anticonvulsant therapy was continued. Serum alkaline phosphatase rose progressively and he became hypocalcaemic (Fig. 4) . In June 1975 he complained (Reiss et al., 1969; O'Riordan et al., 1970) . Histological studies both in acute renal failure (Zech et al., 1973) and chronic renal failure (Ellis and Peart, 1973; Malluche et al., 1976 ) also confirm that osteitis fibrosa is the earliest and predominant histopathological lesion. Osteomalacia with a mineralization deficit may be superimposed on osteitis fibrosa at any level of renal failure and though deficiency of 1,25(OH)2D. is a very important contributing factor, other still poorly-understood mechanisms must operate together and contribute to the development of osteomalacia in these patients (Malluche et al., 1976) .
In children the situation has become unnecessarily complicated historically by the development of two antagonistic schools of thought, one favouring osteitis fibrosa, the other osteomalacia, as the significant underlying bone disorder, though in all large histopathological series of 'renal rickets' there are examples ofboth pure osteitis fibrosaand mixtures of osteitis fibrosa with osteomalacia (Gilmour, 1947; Follis, 1950; Hamperl and Wallis, 1933) . Thus, Stanbury and his colleagues (Stanbury, 1957; Stanbury and Lumb, 1962; Stanbury et al., 1969) , arguing against Albright and Reinfenstein's (1948) idea that renal rickets is not rickets at all but osteitis fibrosa, and perhaps impressed by the response to large doses of vitamin D, reached the other view, that renal rickets may be indistinguishable from dietary vitamin D deficiency rickets. Clearly the truth lies between these two extremes. Experience in our centre indicates that in uraemic children with radiological 'rickets', osteitis fibrosa is a universal finding but that in some of them there is additional osteomalacia, as defined by the presence of excess osteoid, wide osteoid seams with more than 4 birefringent lamellae, and a reduced calcification front (e.g. Case 2).
These children with radiological rickets should be clearly distinguished from children with slipped epiphyses and metaphyseal fractures who have histologically severe osteitis fibrosa and no osteomalacia (e.g. Case 3) (Mehls et al., 1975; Stanbury, 1957) . Interestingly, however, both these lesions respond to treatment with active vitamin D metabolites, in our patients 1,25(OH)2D3, indicating that both osteitis fibrosa and osteomalacia in these children are the result of 1,25(OH)2D3 deficiency. Recognition of the relationship between osteitis fibrosa and 1,25 (OH)2D3 deficiency has important therapeutic implications, for treating these children with aluminium hydroxide alone in the belief that their osteitis fibrosa is the result of uraemic phosphate retention (Slatopolsky et al., 1971) can result in marked worsening of their osteodystrophy (Dent et al., 1961) . Vitamin D should be the mainstay of treatment in uraemic children with either renal rickets or slipped epiphyses.
Effect of anticonvulsant drugs on renal osteodystrophy. The adverse effect of hepatic microsomal enzyme inducing drugs such as phenobarbitone and phenytoin on the calcium and vitamin D metabolism of nonuraemic children is now well described (Richens and Rowe, 1970; Silver et al., 1974; Hahn et al., 1975 ). It appears that in uraemic patients anticonvulsant drugs have an even greater detrimental effect on vitamin D metabolism (Pierides et al., 1976a, b) . 2 of our 3 cases highlight these iatrogenic complications, which may in fact be commoner in children who have increased tendency towards convulsions and need treatment with anticonvulsants. Not only do such anticonvulsant drugs increase the incidence of severe uraemic osteodystrophy, but they also influence the response to treatment with vitamin D. In agreement with previous observations (Chan et al., 1975; Pierides et al., 1976b ), 2 ,tg and then 6 ,tg of daily oral I acOHD3 given to Case 2 (Fig. 4) failed to induce either a clinical or biochemical improvement, whereas 1 ,25(OH)2D3 was dramatically effective. The failure of 1 aOHD3 is presumed to be the result of interference with its required hepatic 25-hydroxylation before its metabolic effects are mediated. In Case 3, it is probable that the unusually severe degrees of metaphyseal destruction and fracturing was the result of the unfortunate combination of uraemia with anticonvulsant therapy, thus depleting 1,25(OH)2D. stores even more.
Cases 2 and 3 show clearly the need for careful consideration of all drugs given to uraemic children, In view of their large vitamin D requirements, children are more vulnerable to anticonvulsant drugs than adults and extra care should be taken in the presence of uraemia. It is likely that regular vitamin D supplements, particularly 1,25(OH)2D3, should be given to any uraemic child started on longterm anticonvulsant drugs. It is of interest that initial studies with sodium valproate suggest this drug may not possess any hepatic microsomal enzyme inducing properties (Jordan et al., 1976) . Clearly if these initial observations are confirmed in humans, sodium valporate will prove a very useful anticonvulsant drug.
Aluminium hydroxide-phosphate deficiency. Case 1 is unusual in view of the severe destructive epiphyseal and metaphyseal changes. In retrospect the clinical deterioration started after the introduction of aluminium hydroxide and though no hypophosphataemia was noted it is likely that phosphate deficiency contributed to the development of the marked osteodystrophy. Severe bone changes and osteomalacia are well known to occur in animals on a phosphate-deficient diet (Day and McCollum, 1939) and hypophosphataemia need not always be present in phosphate deficiency (Dent et al., 1961; Clarkson et al., 1972) . Dodge and Travis (1965) described 2 children who developed phosphatedeficiency rickets after treatment with aluminium hydroxide, and Case 3 in the study by Dent et al., (1961) (Brickman et al., 1974; Henderson et al., 1974; Silverberg et al., 1975; Pierides et al., 1975) It should be noted that in Case 2, though there was a dramatic histological improvement of osteomalacia after 1,25(OH)2D3 with a reduction in the amount of osteoid, reduced width of osteoid seams, and a reduction in the proportion of bone surface comprising osteoid, the calcification front did not return to normal and in many seams was coarsely granular in appearance. We have previously noted that the calcification front does not return entirely to normal in some renal patients treated with 1,25(OH)2D3 (Pierides et al., 1975) or with 1ocOHD3 (Pierides et al., 1976c) . Once the bone had mineralized the amount of mineralized bone exposed to resorption increased and presumably this accounts for the irregular thinning of trabeculae and loss of total bone in the post-treatment biopsy when there was still mild active osteitis fibrosa.
It is worth re-emphasizing that 1,25(OH)2D3 is effective in reducing secondary hyperparathyroidism with improvement of histological osteitis fibrosa as well as osteomalacia. Thus Case 3 with no histological evidence of osteomalacia but only osteitis fibrosa showed an impressive clinical and radiological response after 3 months of 1,25(OH),D3. In Case 2 both the osteomalacia and osteitis fibrosa improved (see Table) . An 
